Core Viewpoint - After a decade of collaboration in the insulin sector, China Resources has decided to divest from Tianmai Biotech, indicating a strategic shift towards focusing on core business operations and asset optimization [1][3]. Company Summary - China Resources Pharmaceutical announced plans to publicly transfer approximately 17.87% of its stake in Tianmai Biotech, with a base price of around 1.42 billion yuan, valuing Tianmai at approximately 8 billion yuan [1][3]. - Following this transaction, China Resources' stake will decrease from 20% to 5.88%, effectively ending its position as the largest shareholder [3]. - The partnership began in 2016 during a period of growth in the domestic insulin market, with China Resources investing in Tianmai due to its technological capabilities in recombinant human insulin [5][6]. - Tianmai Biotech has faced setbacks, particularly with its oral insulin product, which failed to gain regulatory approval, impacting its competitive edge and leading to a reevaluation of its future prospects by China Resources [6][9]. Industry Summary - The insulin market in China has become increasingly competitive, with price reductions due to centralized procurement policies and the emergence of local leaders like Ganli Pharmaceutical and Tonghua Dongbao [8]. - The failure of Tianmai's oral insulin product has raised concerns about its product pipeline and growth potential, making it difficult for the company to align with China Resources' core business focus [7][9]. - The divestment reflects broader challenges faced by domestic biotech firms in maintaining capital support and commercial viability amidst high investment risks in innovative drug development [9].

Group 1 - The company Dongyangguang Pharmaceutical has received approval from the National Medical Products Administration of China for its SGLT-2 inhibitor, Ologliptin capsules, which are intended for improving blood glucose control in adults with type 2 diabetes [1] - The approval is based on two Phase III clinical trials that demonstrated statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with improvements in fasting blood glucose and postprandial blood glucose [1] - The product also showed additional metabolic benefits, including weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood glucose, weight, and blood pressure [1] Group 2 - Diabetes is now the third most serious chronic non-communicable disease globally, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The company has a comprehensive product line in diabetes treatment, including five insulin products that have been approved and are consistent in effectiveness, safety, and quality with original formulations [2] - The new product approval will enhance the company's diabetes product portfolio, and the company plans to leverage its established production system and marketing network for rapid commercialization while exploring further clinical applications for diabetes complications [2]

Group 1 - The company Dongyangguang Pharmaceutical has received approval from the National Medical Products Administration of China for its innovative drug, Ologliptin capsules, which are designed to improve blood sugar control in adults with type 2 diabetes [1] - The approval is based on two Phase III clinical trials that demonstrated statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with improvements in fasting blood glucose and postprandial blood glucose [1] - The product also offers additional metabolic benefits such as weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood sugar, weight, and blood pressure [1] Group 2 - Diabetes has become the third most serious chronic non-communicable disease globally, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The company has a comprehensive product line in the diabetes treatment field, including five insulin products that have been approved and are consistent in efficacy, safety, and quality with original formulations [2] - The approval of the new product will enhance the company's diabetes product portfolio, and it plans to leverage its established production system and marketing network for rapid commercialization while exploring further clinical applications for diabetes complications [2]

Group 1 - Dongyangguang Pharmaceutical (06887.HK) announced that its self-developed SGLT-2 inhibitor, Oloklignet capsules (brand name: Dongzean, specifications: 20mg, 50mg), received approval from the National Medical Products Administration of China for marketing, aimed at improving blood glucose control in adult patients with type 2 diabetes, either as monotherapy or in combination with metformin [1] - The registration approval was based on two multicenter, randomized, double-blind, placebo-controlled Phase III clinical studies, which showed statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with significant improvements in fasting blood glucose and postprandial blood glucose [1] - The product also demonstrated additional metabolic benefits, including weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood glucose, weight, and blood pressure [1] Group 2 - Diabetes has become the third most serious chronic non-communicable disease globally, following cancer and cardiovascular diseases, with the International Diabetes Federation reporting a diabetes prevalence rate of 13.79% among adults (ages 20-79) in China, translating to approximately 148 million patients, the highest in the world [2] - Over 90% of these cases are type 2 diabetes, with a poor medication adherence rate and an effective blood glucose control rate of only 50.1% [2] - The company has a comprehensive product line in the diabetes treatment field, having developed five insulin products that have been approved for marketing, all of which are consistent in efficacy, safety, and quality with original formulations and have been included in the national drug centralized procurement [2] - The approval of the new product will further enrich the company's diabetes product line, leveraging its established production system and marketing network for rapid commercialization, while also exploring clinical applications in diabetes complications to expand the range of indications [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 自願性公告 – 1 – 目前，糖尿病已成為全球範圍內繼腫瘤、心腦血管病之後，第三位嚴重危害人類 健康的慢性非傳染性疾病。國際糖尿病聯盟(IDF)第11版《糖尿病地圖》數據顯示， 中 國 成 人（ 20 – 79 歲 ）糖 尿 病 患 病 率 達 13.79 % ， 患 者 數 量 達 1.48 億 ， 位 居 全 球 首 位 。 其 中 2 型 糖 尿 病 佔 比 超 90 % ， 患 者 臨 床 用 藥 依 從 性 普 遍 不 佳 ， 血 糖 有 效 控 制 率僅有50.1 %。 本集團長期深耕糖尿病治療領域，擁有全面的產品規劃，佈局了完整的產品線。 本集團 ...

Group 1 - The core point of the news is that Tonghua Dongbao's stock price increased by 5.25% to 9.02 CNY per share, with a trading volume of 436 million CNY and a turnover rate of 2.53%, resulting in a total market capitalization of 17.666 billion CNY [1] - Tonghua Dongbao Pharmaceutical Co., Ltd. is primarily engaged in the production of biological products, with 90.29% of its revenue coming from raw materials and formulations, while medical devices account for 6.07%, traditional Chinese medicine and chemical drugs for 2.24%, and other sources for 1.27% [1] - The company was established on December 28, 1992, and went public on August 24, 1994, with its main products including hard capsules, tablets (including hormone types), granules, small-volume injections, and raw materials (recombinant human insulin) [1] Group 2 - Among the top ten circulating shareholders of Tonghua Dongbao, a fund under Yinhua Fund holds a position, having reduced its holdings by 6.308 million shares in the second quarter, now holding 11.0713 million shares, which is 0.57% of the circulating shares [2] - The fund, named Innovation Medicine (159992), has achieved a year-to-date return of 28.18%, ranking 1649 out of 4220 in its category, and a one-year return of 22.33%, ranking 2081 out of 3857 [2] - The fund manager, Ma Jun, has a tenure of 13 years and 45 days, with a total fund size of 33.304 billion CNY, achieving a best return of 144.61% and a worst return of -75.62% during his tenure [3]